Efficacy and safety of oral decitabine/cedazuridine (astx727) in the cmml subpopulation from phase 2 and ascertain phase 3 studies

M. Savona,J. Mccloskey,E. Griffiths,K. Yee, A. Zeidan, A. Al-Kali,H. J. Deeg,P. Patel,M. Sabloff,M. -M. Keating,N. Zhu,N. Gabrail,S. Fazal, J. Maly,O. Odenike,H. Kantarjian,A. Dezern,C. O'Connell, G. Roboz,L. Busque, R. Buckstein, H. Amin, J. Randhawa,B. Leber, K. -H. Dao, Y. Sano, B. Mirakhur,H. Keer,G. Garcia-Manero

LEUKEMIA RESEARCH(2023)

Cited 0|Views5
No score
Key words
MDS, oral decitabine/cedazuridine, oral, hypomethylating agent, CMML, phase II, phase III
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined